Inspections, Compliance, Enforcement, and Criminal Investigations
Glyco-Meds, LLC 5/19/09
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740
FROM: Food and Drug Administration
RE: Unapproved/Uncleared/Unauthorized Products Related to the H1N1 Flu Virus
DATE: May 19, 2009
This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.glyco-meds.com on May 14, 2009. The FDA has determined that your website offers products for sale that are intended to diagnose, mitigate, prevent, treat or cure the H1N1 Flu Virus in people. These products have not been approved, cleared, or otherwise authorized by FDA for use in the diagnosis, mitigation, prevention, treatment, or cure of the H1 N1 Flu Virus. These products are Cold Booster Formula and Cold Booster Plus Formula. The marketing of these products violates the Federal Food, Drug, and Cosmetic Act (FFDC Act). 21 U.S.C. §§ 331, 351, 352. We request that you immediately cease marketing unapproved, uncleared, or unauthorized products for the diagnosis, mitigation, prevention, treatment, or cure of the H1N1 Flu Virus.
Some examples of the claims on your website include:
Cold Booster Formula
• "The ingredients in our Cold Booster Formula have been shown to be effective against ... flu viruses.... In field testing this formula has been shown to be extremely effective against Group 5 viruses. Some examples of these Group 5 (RNA) viruses are: ... Flu ... Swine Flu."
Cold Booster Plus Formula
• "The ingredients in our Cold Booster Plus Formula have been shown to be much more effective against fighting ... Influena [sic] viruses Types A (Swine Flu) and B than any prescription medication known."
• "In recent human field tests this composition has been shown to be extremely effective against most Group 1 and Group 5 viruses.... Group 5 (RNA) viruses include: ... Influenza virus A and B, Swine Flu ...."
• Your website includes a press release entitled "New Swine Flu Cure only Requires OneCapsule" which states, in part:
"After many years of research GlycoMeds has developed a broad spectrum antiviral product that kills the Swine Flu virus very quickly. Human testing has shown that one capsule can kill a whole body viral infection in four to eight hours even if several days into the infection. Unlike all of the competing flu products on the market today that just treat symptoms GlycoMeds' product is the only one that actually kills the virus within a few hours which automatically eliminates all symptoms. In independent testing this product has been shown to be hundreds of times more effective at killing flu virus then the most potent anti-viral prescription medications known."
• Your "Product Usage" page includes a chart of "Health Interests" with corresponding "Patent Pending Product[s)" and "Suggested Usage." This chart includes a line stating that for "Swine Flu (Influenza A)" the product you suggest is "Cold Booster Plus Capsule," to be taken "once a day for two days[.]"
"Recent testing of our Patent Pending Cold Booster and Patent Pending Cold Booster Plus compositions has shown that from ingestion to time to kill the invading virus is ... under four hours for an influenza whole body type of infection."
The Secretary of Health and Human Services, under section 319 of the Public Health Service Act, 42 U.S.C. § 247d, has determined that a public health emergency exists nationwide involving the H1N1 Flu Virus that affects or has the significant potential to affect national security. Following this determination and in response to requests from the U.S. Centers for Disease Control and Prevention, FDA issued letters authorizing the emergency use of certain unapproved and uncleared products or unapproved or uncleared uses of approved or cleared products, provided certain criteria are met, under 21 U.S.C. § 360bbb-3. The marketing and sale of unapproved or uncleared H1 N1 Flu Virus -related products that are not authorized by and used in accordance with the conditions of an Emergency Use Authorization, is a potentially significant threat to the public health. Therefore, FDA is taking urgent measures to protect consumers from products that, without approval or authorization by FDA, claim to diagnose, mitigate, prevent, treat or cure H1N1 Flu Virus in people.
You should take immediate action to ensure that your firm is not marketing, and does not market in the future, products intended to diagnose, mitigate, prevent, treat or cure the H1N1 Flu Virus that have not been approved, cleared, or authorized by the FDA. The above is not meant to be an all-inclusive list of violations. It is your responsibility to ensure that the products you market are in compliance with the FFDC Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that the claims you make for your products do not adulterate or misbrand the products in violation of the FFDC Act. 21 U.S.C. §§ 331, 351, 352. Within 48 hours, please send an email to FDAFLUTASKFORCE-CDRH@fda.hhs.gov, describing the actions that you have taken or plan to take to address your firm's violations. If your firm fails to take corrective action immediately, FDA may take enforcement action, such as seizure or injunction for violations of the FFDC Act without further notice. Firms that fail to take corrective action may also be referred to FDA's Office of Criminal Investigations for possible criminal prosecution for violations of the FFDC Act and other federal laws.
FDA is advising consumers not to purchase or use H1N1 Flu Virus-related products offered for sale that have not been approved, cleared, or authorized by FDA. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning marketing unapproved/uncleared, and unauthorized H1N1 Flu Virus-related products in violation of the FFDC Act. This list can be found at www.accessdata.fda.gov/scripts/h1n1flu. Once the violative claims and/or products have been removed from your website, and these corrective actions have been confirmed by the FDA, the
published list will be updated to indicate that your firm has taken appropriate corrective action.
If you are not located in the United States, please note that unapproved, uncleared, or unauthorized products intended to diagnose, mitigate, prevent, treat, or cure the H1N1 Flu Virus offered for importation into the United States are subject to detention and refusal of admission. We will advise the appropriate regulatory or law enforcement officials in the country from which you operate that FDA considers your products listed above to be unapproved, uncleared, or unauthorized products that cannot be legally sold to consumers in the United States.
Please direct any inquiries concerning this letter to FDA at FDAFLUTASKFORCE-CDRH@fda.hhs.gov or by contacting Latasha A. Robinson at 301-436-1890.
Office of Compliance
Center for Food Safety
and Applied Nutrition